Advanced well-differentiated/dedifferentiated liposarcomas: Role of chemotherapy and survival

Annals of Oncology

Volumn 23, Issue 6, 2012, Pages 1601-1607

  Italiano, A ^a,b   Toulmonde, M ^a   Cioffi, A ^b,c   Penel, N ^d   Isambert, N ^e   Bompas, E ^f   Duffaud, F ^g   Patrikidou, A ^c   Lortal, B ^a   Le cesne, A ^c   Blay, J Y ^h   Maki, R G ^b,i   Schwartz, G K ^b   Antonescu, C R ^b   Singer, S ^b   Coindre, J M ^a   Bui, B ^a  

^a INSTITUT BERGONIÉ   (France)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c Institut Gus tave Roussy   (France)

^d CENTRE OSCAR LAMBRET   (France)

^e CENTRE GEORGES FRANÇOIS LECLERC   (France)

^f CENTRE RENÉ GAUDUCHEAU   (France)

^g TIMONE HOSPITAL   (France)

^h CENTRE LÉON BÉRARD   (France)

ⁱ MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy; Dedifferentiated liposarcomas; Liposarcoma; Prognosis; Treatment; Well differentiated liposarcomas

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DACARBAZINE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; TRABECTEDIN;

ADULT; ADVANCED CANCER; AGE; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; DEDIFFERENTIATED LIPOSARCOMA; FEMALE; FUNCTIONAL STATUS; HUMAN; LIPOSARCOMA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL TIME; TREATMENT RESPONSE; WELL DIFFERENTIATED LIPOSARCOMA;

EID: 84861719494     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr485     Document Type: Article

References (38)

1. Fletcher CDM, Unni KK, Mertens F. Pathology and genetics of tumours of soft tissue and bone. In Kleihues P (ed), World Health Organisation Classification of Tumours, Edition (pp. 35-46). Lyon, France: IARC Press 2002.
2. Italiano A, Bianchini L, Keslair F et al. HMGA2 is the partner of MDM2 in welldifferentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon. Int J Cancer 2008; 122: 2233-2241.
3. Binh MB, Sastre-Garau X, Guillou L et al. MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data. Am J Surg Pathol 2005; 29: 1340-1347.
4. Aleixo PB, Hartmann AA, Menezes IC et al. Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours. J Clin Pathol 2009; 62: 1127-1135.
5. Coindre JM, Mariani O, Chibon F et al. Most malignant fibrous histiocytomas developed in the retroperitoneum are dedifferentiated liposarcomas: a review of 25 cases initially diagnosed as malignant fibrous histiocytoma. Mod Pathol 2003; 16: 256-262.
6. de Vreeze RS, de Jong D, Nederlof PM et al. Added value of molecular biological analysis in diagnosis and clinical management of liposarcoma: a 30-year singleinstitution experience. Ann Surg Oncol 2010; 17: 686-693.
7. Mussi C, Collini P, Miceli R et al. The prognostic impact of dedifferentiation in retroperitoneal liposarcoma: a series of surgically treated patients at a single institution. Cancer 2008; 113: 1657-1665.
8. Coindre JM, Pedeutour F, Aurias A. Well-differentiated and dedifferentiated liposarcomas. Virchows Arch 2010; 456: 167-179.
9. Lucas DR, Nascimento AG, Sanjay BK, Rock MG. Well-differentiated liposarcoma. The Mayo Clinic experience with 58 cases. Am J Clin Pathol 1994; 102: 677-683.
10. Henricks WH, Chu YC, Goldblum JR, Weiss SW. Dedifferentiated liposarcoma: a clinicopathological analysis of 155 cases with a proposal for an expanded definition of dedifferentiation. Am J Surg Pathol 1997; 21: 271-281.
11. Dalal KM, Kattan MW, Antonescu CR et al. Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk. Ann Surg 2006; 244: 381-391.
12. Singer S, Antonescu CR, Riedel E, Brennan MF. Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. Ann Surg 2003; 238: 358-370; discussion 370-351.
13. Jones RL, Fisher C, Al-Muderis O, Judson IR. Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur J Cancer 2005; 41: 2853-2860.
14. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
15. Casali PG, Blay JY. Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 (Suppl 5): v198-v203.
16. Van Glabbeke M, van Oosterom AT, Oosterhuis JW et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens-a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 1999; 17: 150-157.
17. Patel SR, Burgess MA, Plager C et al. Myxoid liposarcoma. Experience with chemotherapy. Cancer 1994; 74: 1265-1269.
18. Borden EC, Amato DA, Rosenbaum C et al. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol 1987; 5: 840-850.
19. Antman K, Crowley J, Balcerzak SP et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 1993; 11: 1276-1285.
20. Edmonson JH, Ryan LM, Blum RH et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993; 11: 1269-1275.
21. Schoenfeld DA, Rosenbaum C, Horton J et al. A comparison of adriamycin versus vincristine and adriamycin, and cyclophosphamide versus vincristine, actinomycin-D, and cyclophosphamide for advanced sarcoma. Cancer 1982; 50: 2757-2762.
22. Borden EC, Amato DA, Edmonson JH et al. Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft-tissue sarcomas. Cancer 1990; 66: 862-867.
23. Santoro A, Tursz T, Mouridsen H et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995; 13: 1537-1545.
24. Verma S, Younus J, Stys-Norman D et al. Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma. Cancer Treat Rev 2008; 34: 339-347.
25. Karavasilis V, Seddon BM, Ashley S et al. Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients. Cancer 2008; 112: 1585-1591.
26. Sleijfer S, Ouali M, van Glabbeke M et al. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). Eur J Cancer 2010; 46: 72-83.
27. Blay JY, van Glabbeke M, Verweij J et al. Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. Eur J Cancer 2003; 39: 64-69.
28. Ray-Coquard I, Cropet C, Van Glabbeke M et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res 2009; 69: 5383-5391.
29. Penel N, Glabbeke MV, Mathoulin-Pelissier S et al. Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcoma: the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (STBSG) and French Sarcoma Group (FSG) study. Br J Cancer 2011; 104: 1544-1550.
30. Muller CR, Paulsen EB, Noordhuis P et al. Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A. Int J Cancer 2007; 121: 199-205.
31. Ray-Coquard IL, Blay J, Italiano A et al. Neoadjuvant MDM2 antagonist RG7112 for well-differentiated and dedifferentiated liposarcomas (WD/DD LPS): a pharmacodynamic (PD) biomarker study. J Clin Oncol 2011; 29 (Suppl): (Abstr 10007b).
32. Italiano A, Bianchini L, Gjernes E et al. Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas. Clin Cancer Res 2009; 15: 5696-5703.
33. Tontonoz P, Singer S, Forman BM et al. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci U S A 1997; 94: 237-241.
34. Demetri GD, Fletcher CD, Mueller E et al. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci U S A 1999; 96: 3951-3956.
35. Debrock G, Vanhentenrijk V, Sciot R et al. A phase II trial with rosiglitazone in liposarcoma patients. Br J Cancer 2003; 89: 1409-1412.
36. Pishvaian MJ, Cotarla I, Wagner AJ et al. Final reporting of a phase I clinical trial of the oral PPAR-gamma agonist, CS-7017, in patients with advanced malignancies. J Clin Oncol 2010; 28 (Suppl): (Abstr 2526).
37. Dass CR, Galloway SJ, Clark JC et al. Involvement of c-jun in human liposarcoma growth: supporting data from clinical immunohistochemistry and DNAzyme efficacy. Cancer Biol Ther 2008; 7: 1297-1301.
38. Peng T, Zhang P, Liu J et al. An experimental model for the study of welldifferentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors. Lab Invest 2011; 91: 392-403.